Table 2 Fourteen combinations of omic analyses for rare disease research
From: A scoping review and proposed workflow for multi-omic rare disease research
‘Omic’ analyses combination | Number of Studies (n = 66) | Percentage |
|---|---|---|
Epigenomics, genomics | 1 | 1.52% |
Epigenomics, genomics, proteomics, transcriptomics (TCGA) | 13 | 19.70% |
Epigenomics, genomics, transcriptomics | 9 | 13.64% |
Epigenomics, proteomics, transcriptomics | 2 | 3.03% |
Epigenomics, transcriptomics | 1 | 1.52% |
Genomics, metabolomics | 4 | 6.06% |
Genomics, metabolomics, phenomics | 1 | 1.52% |
Genomics, phenomics | 1 | 1.52% |
Genomics, phenomics, transcriptomics | 2 | 3.03% |
Genomics, proteomics | 7 | 10.61% |
Genomics, proteomics, transcriptomics | 8 | 12.12% |
Genomics, transcriptomics | 13 | 19.70% |
Metabolomics, proteomics | 1 | 1.52% |
Proteomics, transcriptomics | 3 | 4.55% |